Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial

Archives of Ophthalmology

Volumn 126, Issue 12, 2008, Pages 1707-1715

  White, Neil H ^ai   Sun, Wanjie ^ai   Cleary, Patricia A ^ai   Danis, Ronald P ^ai   Davis, Matthew D ^ai   Hainsworth, Dean P ^ai   Hubbard, Larry D ^ai   Lachin, John M ^ai   Nathan, David M ^g   Crofford, O ^ai   Crandall, J ^a   Phillips, M ^a   Reid, M ^a   Brown Friday, J ^a   Engel, S ^a   Sheindlin, J ^a   Martinez, H ^a   Shamoon, H ^a   Engel, H ^a   Dahms, W ^b   Palmert, M ^b   Gubitosi Klug, R ^b   Mayer, L ^b   Pendegras, S ^b   Zegarra, H ^b   Miller, D ^b   Singerman, L ^b   Smith Brewer, S ^b   Novak, M ^b   Gaston, P ^b   Genuth, S ^b   Brillon, D ^c   Lackaye, M E ^c   Reppucci, V ^c   Lee, T ^c   Heinemann, M ^c   Whitehouse, F ^d   McLellan, M ^d   Kruger, D ^d   Carey, J D ^d   Angus, E ^d   Croswell, M ^d   Galpirn, A ^d   Bergenstal, R ^e   Johnson, M ^e   Spencer, M ^e   Morgan, K ^e   Etzwiler, D ^e   Kendall, D ^e   Noller, D ^e   Jacobson, A ^f   Golden, E ^f   Beaser, R ^f   Ganda, O ^f   Hamdy, O ^f   Rosenzweig, J ^f   Wolpert, H ^f   Sharuk, P G ^f   Arrigg, P ^f   Burwood, A ^f   Rand, L ^f   Larkin, M ^g   Godine, J ^g   Moore, D ^g   Cagliero, E ^g   Lou, P ^g   Fritz, S ^g   Service, J ^h   Ziegler, G ^h   Pach, J ^h   Colligan, R ^h   Lopes Virella, M ⁱ   Colwell, J ⁱ   Hermayer, K ⁱ   Brabham, M ⁱ   Soule, J ⁱ   Blevins, A ⁱ   Parker, J ⁱ   Lee, D ⁱ   Lindsey, P ⁱ   Bracey, M ⁱ   Lee, K ⁱ   Nutaitis, M ⁱ   Farr, A ⁱ   Elsing, S ⁱ   Thompson, T ⁱ   Selby, J ⁱ   Lyons, T ⁱ   Yacoub Wasef, S ⁱ   Szpiech, M ⁱ   Wood, D ⁱ   Mayfield, R ⁱ   Molitch, M ^j   Schaefer, B ^j   Jampol, L ^j   Lyon, A ^j   Gill, M ^j   Strugula, Z ^j   Kaminski, L ^j   Shankle, J ^j   Astlesford, P ^j   Blackburn, D ^j   Ajroud Driss, S ^j   Stone, O ^j   West, C ^j   Burnett Zeigler, I ^j   Kolterman, O ^k   Lorenzi, G ^k   Goldbaum, M ^k   Harvey, K ^k   Ferreyra, H ^k   Sivitz, W ^l   Bayless, M ^l   Weingeist, T ^l   Stone, E ^l   Culver Boldt, H ^l   Gehres, K ^l   Russell, S ^l   Bayless, J ^l   Kramer, J ^l   Long, J ^l   Zeither, R ^l   Hebdon, M ^m   Donner, T ^m   Johnsonbaugh, S ^m   Gordon, J ^m   Hemady, R ^m   Kowarski, A ^m   Ostrowski, D ^m   Steidl, S ^m   Jones, B ^m   Counts, D ^m   Herman, W ⁿ   Martin, C ⁿ   Pop Busui, R ⁿ   Vine, A K ⁿ   Elner, S ⁿ   Feldman, E ⁿ   Albers, J ⁿ   Greene, D ⁿ   Stevens, M J ⁿ   Bantle, J ^o   Rogness, B ^o   Olsen, T ^o   Steuer, E ^o   Rath, P ^o   Hitt, S ^p   Giangiacom, J ^p   Goldstein, D ^p   Schade, D ^q   Canady, J ^q   Schluter, J M ^q   Das, A ^q   Hornbeck, D ^q   Schwartz, S ^r   Bourne, P A ^r   Maschak Carey, B J ^r   Baker, L ^r   Braunstein, S ^r   Brucker, A ^r   Orchard, T ^s   Silvers, N ^s   Ryan, C ^s   Songer, T ^s   Doft, B ^s   Olson, S ^s   Bergren, R L ^s   Lobes, L ^s   Paczan Rath, P ^s   Becker, D ^s   Drash, A ^s   Morrison, A ^t   Vaccaro Kish, J ^t   Bernal, M L ^t   Malone, J ^t   Pavan, P R ^t   Grove, N ^t   Iyer, M N ^t   Burrows, A F ^t   Tanaka, E A ^t   Gstalder, R ^t   Dagogo Jack, S ^u   Wigley, C ^u   Ricks, H ^u   Kitabchi, A ^u   Murphy, M B ^u   Moser, S ^u   Meyer, D ^u   Iannacone, A ^u   Chaum, E ^u   Yoser, S ^u   Bryer Ash, M ^u   Schussler, S ^u   Lambeth, H ^u   Raskin, P ^v   Strowig, S ^v   Ufret, R ^v   He, Y G ^v   Edwards, A ^v   Alappatt, J ^v   Wilson, C ^v   Park, S ^v   Zinman, B ^w,ah   Barnie, A ^w   MacLean, S ^w   Devenyi, R ^w   Mandelcorn, M ^w   Brent, M ^w   Rogers, S ^w   Gordon, A ^w   Palmer, J ^x   Catton, S ^x   Brunzell, J ^x   Ginsberg, J ^x   Kinyoun, J ^x   Van Ottingham, L ^x   Dupre, J ^y   Harth, J ^y   Nicolle, D ^y   Canny, C ^y   May, M ^z   Lipps, J ^z   Agarwal, A ^z   Adkins, T ^z   Survant, L ^z   Lorenz, R ^z   Feman, S ^z   Levandoski, L ^aa   Boniuk, I ^aa   Grand, G ^aa   Thomas, M ^aa   Burgess, D ^aa   Joseph, D ^aa   Blinder, K ^aa   Shah, G ^aa   Santiago, J ^aa   Tamborlane, W ^ab   Gatcomb, P ^ab   Stoessel, K ^ab   Taylor, K ^ab   Trail, R ^b   Quin, J ^b   Kenny, D ^ac   Backlund, J ^ac   Rutledge, B ^ac   Waberski, B ^ac   Klumpp, K ^ac   Chan, K ^ac   Diminick, L ^ac   Rosenberg, D ^ac   Petty, B ^ac   Determan, A ^ac   Williams, C ^ac   Dews, L ^ac   Hawkins, M ^ac   Cowie, C ^ai   Fradkin, J ^ai   Siebert, C ^ai   Eastman, R ^ai   Geithman, P ^ad   Kastorff, L ^ad   Neider, M ^ad   Badal, D ^ad   Esser, B ^ad   Miner, K ^ad   Wabers, H ^ad   Glander, K ^ad   Joyce, J ^ad   Robinson, N ^ad   Hurtenbach, C ^ad   Hannon, C ^ad   Steffes, M ^o   Bucksa, J ^o   Chavers, B ^o   O'Leary, D ^ae   Funk, L ^ae   Polak, J ^ae   Harrington, A ^ae   Crow, R ^o   Gloeb, B ^o   Thomas, S ^o   O'Donnell, C ^o   Prineas, R ^af   Campbell, C ^af   Sandstrom, D ^ai   Williams, T ^ai   Geckle, M ^ai   Cupelli, E ^ai   Thoma, F ^ai   Burzuk, B ^ai   Woodfill, T ^ai   Low, P ^h   Sommer, C ^h   Nickander, K ^h   Detrano, R ^ag   Wong, N ^ag   Fox, M ^ag   Kim, L ^ag   Oudiz, R ^ag   Weir, G ^ai   Clark, C ^ai   D'Agostino, R ^ai   Espeland, M ^ai   Klein, B ^ai   Manolio, T ^ai   Singer, D ^ai   Stern, M ^ai   Garvey, W T ⁱ   Jenkins, A ⁱ   Klein, R ⁱ   Virella, G ⁱ   Jaffa, A A ⁱ   Lackland, D ⁱ   McGee, D ⁱ   Zheng, D ⁱ   Paterson, A ^ah   Boright, A ^ah   Bull, S ^ah   Sun, L ^ah   Scherer, S ^ah   Hokanson, J ^x   Marcovina, S ^x   Purnell, J ^x   Sibley, S ^x   Deeb, S ^x   Edwards, K ^x   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e INTERNATIONAL DIABETES CENTER   (United States)

^f JOSLIN DIABETES CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MAYO CLINIC   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF IOWA   (United States)

^m UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MICHIGAN   (United States)

^o UNIVERSITY OF MINNESOTA   (United States)

^p UNIVERSITY OF MISSOURI   (United States)

^q UNIVERSITY OF NEW MEXICO   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s UNIVERSITY OF PITTSBURGH   (United States)

^t UNIVERSITY OF SOUTH FLORIDA   (United States)

^u UNIVERSITY OF TENNESSEE   (United States)

^v SOUTHWESTERN UNIVERSITY   (United States)

^w UNIVERSITY OF TORONTO   (Canada)

^x UNIVERSITY OF WASHINGTON   (United States)

^y UNIVERSITY OF WESTERN ONTARIO   (Canada)

^z VANDERBILT UNIVERSITY   (United States)

^aa WASHINGTON UNIVERSITY   (United States)

^ab YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac GEORGE WASHINGTON UNIVERSITY   (United States)

^ad University of Wisconsin   (United States)

^ae TUFTS MEDICAL CENTER   (United States)

^af WAKE FOREST UNIVERSITY   (United States)

^ag Harbor UCLA Research   (United States)

^ah HOSPITAL FOR SICK CHILDREN   (Canada)

^ai Hospital for Sick Children ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; ANTIDIABETIC AGENT; HEMOGLOBIN A1C PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLOPATHY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INTENSIVE CARE; INTERVENTION STUDY; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RATING SCALE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CONTROLLED CLINICAL TRIAL; INFUSION PUMP; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INFUSION PUMPS; INSULIN; MALE; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 58149252632     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.126.12.1707     Document Type: Article

References (26)

1. The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-986.
2. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. Diabetes Care. 1999;22(1):99-111.
3. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342(6):381-389.
4. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5)(suppl):823-833.
5. The effect of diabetes therapy on the progression of diabetic retinopathy in insulindependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113(1):36-51.
6. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796-1806.
7. Early Treatment Diabetic Retinopathy Study (ETDRS) Manual of Operations. Springfield, VA: National Technical Information Service; 1985. Accession No. PB85223006.
8. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled agreement or partial credit. Psychol Bull. 1968;70:213-220.
9. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley; 1981:38-46.
10. Steffes M, Cleary P, Goldstein D, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem. 2005;51(4):753-758.
11. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabletes Intervention and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290(16):2159-2167.
12. Snedecor GW, Cochran WG. Statistical Methods. 6th ed. Ames: Iowa State University Press; 1980.
13. Agresti A. Categorical Data Analysis. New York, NY: John Wiley & Sons; 1990: 80-91, 235-236.
14. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
15. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. New York, NY: John Wiley & Sons; 2000.
16. Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics. 1992;48(3):951-959.
17. Turbull BW. The empirical distribution function with arbitrarily censored and truncated data. J R Stat Soc [Ser B]. 1976;38:290-295.
18. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44(8):968-983.
19. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial [published correction appears in Arch Ophthalmol. 1998;116(11):1469]. Arch Ophthalmol. 1998;116(7):874-886.
20. Martin CL, Albers J, Herman WH, et al; DCCT/EDIC Group. Neuropathy among the Diabetes Control and Complications Trial cohort 8 years after trial completion. Diabetes Care. 2006;29(2):340-344.
21. Reichard P. Are there any glycemic thresholds for the serious microvascular complications? J Diabetes Complications. 1995;9(1):25-30.
22. Nathan DM, Cleary PA, Backlund J-YC, et al. Intensive diabetes treatment and cardiovascular disease in type 1 diabetes mellitus. N Engl J Med. 2005;353(25):2643-2653.
23. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36(7):808-812.
24. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biological and clinical implications for diabetes and aging. Lab Invest. 1994;70(2):138-151.
25. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation and crosslinking are lower in subjects with long-term intensive vs. conventional therapy of type I diabetes. Diabetes. 1999;48(4):870-880.
26. Genuth S, Sun W, Cleary P, et al. Levels of glycation and carboxymethyllysine in skin collagen predict future 10 year progression of diabetic retinopathy and nephropathy in DCCT/EDIC participants with type 1 diabetes. Diabetes. 2005;54(11):3103-3111.